MyFinsight
Home
Blog
About
Contact
Download
Download image
Decrease in cash and cash
equivalents
-$4,612K
Accounts payable
$1,957K
Share-based compensation
$1,605K
Prepaid expenses and
other current assets
-$271K
Accrued expenses and
other liabilities
$229K
Amortization of operating
lease right-of-use...
$134K
Amortization of intangible
assets
$127K
Depreciation
$44K
Non-cash interest
expense
$12K
Net cash used in
operating activities
-$4,312K
Net cash used in
investing activities
-$300K
Canceled cashflow
$4,379K
Net loss
-$6,719K
Payments for intangible
assets
$300K
Foreign currency
transaction gain/(loss)
$1,628K
Operating lease
liabilities
-$201K
Research and development
incentives receivable
$95K
Non-cash interest income
$31K
Change in fair value of
warrants
-$17K
Back
Back
Cash Flow
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)
source: myfinsight.com